Login to Your Account

Scenesse Misses EPP Phase III Endpoint, but Still on Track

By Cormac Sheridan
Staff Writer

Tuesday, November 12, 2013
Scenesse (afamelanotide), which Clinuvel Pharmaceuticals Ltd. is developing for the rare light intolerance disorder erythropoietic protoporphyria (EPP), failed to hit the endpoint of a U.S. Phase III trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription